Metformin May Help Decrease BMI in Obese Adolescents
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Metformin May Help Decrease BMI in Obese Adolescents

CHICAGO -- February 1, 2010 -- Metformin extended release (XR) formulation appears to cause a small but significant decrease in body mass index (BMI) in non-diabetic obese adolescents when combined with a lifestyle intervention program, according to a study published in the February issue of Archives of Pediatrics & Adolescent Medicine.

Darrell M. Wilson, MD, Stanford University and the Lucile S. Packard Children’s Hospital, Stanford, California, and colleagues in the Glaser Pediatric Research Network Obesity Study Group conducted a randomised study in 77 obese adolescents aged 13 to 18 years.

Patients received a lifestyle intervention program, consisting of physical activity and diet, and were randomised to receive either 1 daily dose of metformin XR 2,000 mg (n = 39) or placebo (n = 38) for 48 weeks. Participants were monitored for an additional 48 weeks.

“Metformin XR had a small but statistically significant impact on BMI over the initial 52 weeks of the study,” the authors wrote.

The average BMI increased by 0.2 in the placebo group and decreased by 0.9 in the metformin XR group. “The BMI difference between the groups persisted for 12 to 24 weeks after cessation of study drug. Thereafter, the mean BMI in the metformin group increased toward that in the control group.”

“Metformin was safe and tolerated in this population,” the authors wrote. “These results indicate that metformin may have an important role in the treatment of adolescent obesity.”

“Longer-term studies will be needed to define the effects of metformin treatment on obesity-related disease risk in this population,” the authors concluded.

SOURCE: Archives of Pediatrics & Adolescent Medicine

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities